SCHEMBL4860753

SCHEMBL4860753

Cc1ccc(-c2cc3c(c(C(=O)O)c2)OC(c2ccccc2)(c2ccccc2)O3)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 4/20 0.44
AKR1C2 P52895 1/20 0.44
AKR1C1 Q04828 1/20 0.44
FTO Q9C0B1 1/20 0.41
CNR1 P21554 6/20 0.40
UHRF1 Q96T88 1/20 0.39
DHODH Q02127 2/20 0.37
ACMSD Q8TDX5 2/20 0.37
DHFR P00374 1/20 0.37
HNF4A P41235 1/20 0.37
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
AKR1C3 P42330 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PTPN1 P18031 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867176 0.88 NR4A2 (0.41) MCL1AKR1C2AKR1C1FTOCNR1
SCHEMBL4863679 0.87 CNR1 (0.42) MCL1AKR1C2AKR1C1CNR1DHODH
SCHEMBL8285530 0.85 CNR1 (0.44) CNR1AKR1C3KDM4EALDH1A1
SCHEMBL4861896 0.85 DHODH (0.43) AKR1C2AKR1C1FTOCNR1DHODH
SCHEMBL4866066 0.81 HNF4A (0.41) CNR1HNF4AGAAAKR1C3KDM4E
SCHEMBL4870745 0.77 PDPK1 (0.41) MCL1CNR1DHODH
SCHEMBL4868951 0.77 SLC6A4 (0.46) CNR1DHODHNPC1GAARAB9A
SCHEMBL4868360 0.77 CNR1 (0.45) AKR1C2AKR1C1CNR1DHODHKMT2A
SCHEMBL4867081 0.77 CNR1 (0.44) AKR1C2AKR1C1CNR1DHODHKMT2A
SCHEMBL4863705 0.76 CNR1 (0.39) MCL1CNR1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
US-7319101-B2 COMT inhibitors for the treatment of depression and impaired cognition HOFFMANN-LA ROCHE INC. (US) 2008-01-15 US disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2007-03-21 EP disclosed
EP-1697394-A2 COMT INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-09-06 EP disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
WO-2005058228-A2 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition F. HOFFMANN-LA ROCHE AG (CH) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137162-A1 New COMT inhibitors for the treatment of depression and impaired cognition COMT, MAOB, TPH1 MCL1 4536/4885AKR1C2 339/4885AKR1C1 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.